Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vitiligo Diagnosis of non-segmental vitiligo affecting at least 10% of BSA since at least 3 months Patient requiring a treatment by UVB For both female of childbearing potential and male patients: Use of an effective contraceptive method during the study period (see Annex 5 for details) Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted Able to adhere to the study visit schedule and other protocol requirements Patient registered to the French Social Security  Segmental or mixed vitiligo 2. Other than vitiligo, history of any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major uncontrolled disease. 3. Any condition which would place the subject at unacceptable risk if he/she were to participate in the study. 4. Any condition that confounds the ability to interpret data from the study. 5. Pregnant or breast feeding, pregnancy urinary tests will be performed (see Annex 5 for details about pregnancy testing and contraception) 6. History of allergy to any component of apremilast 7. History of positive human immunodeficiency virus (HIV), or have congenital or acquired immunodeficiency (eg, common variable immunodeficiency disease) 8. Active substance abuse or a history of substance abuse within 6 months prior to Screening 9. Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of Screening. Any treatment for such infections must have been completed at least 4 weeks prior to Screening. 10. Malignancy or history of malignancy (except for treated [ie, cured] basal cell or squamous cell in situ skin carcinomas and treated [ie, cured] cervical intraepithelial neoplasia [CIN] or carcinoma in situ of the cervix with no evidence of recurrence) 11. Evidence of skin conditions that would interfere with clinical assessments 12. Topical therapy within 2 weeks of randomization 13. Prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources 14. Prior treatment with apremilast 15. Use of phototherapy within 4 weeks prior to randomization (ie, UVB, PUVA) 16. Use of any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half-lives, 17. Patients assessed to be uncooperative 18. Participants in other clinical studies 19. Vulnerable people: pregnant or breast-feeding women (an urinary pregnancy test will be realized in every visit), minors, adults under guardianship or guardianship, deprived of freedom 20. Patient with a rare hereditary disease such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption syndrome 21. Patient with severe renal insufficiency